23andMe is exploring strategic alternatives, looking to raise capital
23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter results that showed an 8% drop in consumer services revenue year over year. 23andMe said it will "need additional liquidity" to fund its operations, and it is looking to raise additional capital.
For its internal medicines initiatives, the business has started looking for strategic substitutes including possible asset sales or licencing deals. Unless a clear agreement is achieved or legal ...
The Special Committee of the board of 23andMe Holding Co. announced that it has undertaken a process to explore strategic alternatives, including, among other alternatives, a poss ...
Ingevity Corporation NGVT recently announced plans to explore strategic alternatives for its Performance Chemicals Industrial ...
After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on ...
Genetic testing pioneer 23andMe is looking at strategic alternatives, including a possible sale, it said Tuesday, months ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback